| scholarly article | Q13442814 |
| P2093 | author name string | Andrew Bivard | |
| Longting Lin | |||
| Mark W Parsonsb | |||
| P2860 | cites work | The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial | Q24595579 |
| A randomized trial of tenecteplase versus alteplase for acute ischemic stroke | Q28262393 | ||
| Tissue plasminogen activator for acute ischemic stroke | Q29619377 | ||
| A trial of imaging selection and endovascular treatment for ischemic stroke | Q30417276 | ||
| Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial | Q30432880 | ||
| Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset | Q30436402 | ||
| Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data | Q33320002 | ||
| Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. | Q33883119 | ||
| Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis | Q34171137 | ||
| Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. | Q34250891 | ||
| The high cost of not funding stroke research: a comparison with heart disease and cancer | Q34264278 | ||
| Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection | Q34574818 | ||
| Revascularization results in the Interventional Management of Stroke II trial | Q34666805 | ||
| Thrombolysis: newer thrombolytic agents and their role in clinical medicine | Q35574270 | ||
| The pathogenesis of a coronary thrombus | Q35886053 | ||
| Plasminogen activators: a comparison | Q36308287 | ||
| Inflammation and atherosclerosis: novel insights into plaque formation and destabilization | Q36495025 | ||
| Endovascular therapy after intravenous t-PA versus t-PA alone for stroke | Q36837191 | ||
| MRI-based selection for intra-arterial stroke therapy: value of pretreatment diffusion-weighted imaging lesion volume in selecting patients with acute stroke who will benefit from early recanalization | Q37259557 | ||
| Significance of large vessel intracranial occlusion causing acute ischemic stroke and TIA. | Q37486129 | ||
| The molecular basis of thrombolysis and its clinical application in stroke. | Q37696587 | ||
| Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction | Q39220756 | ||
| Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial | Q39561448 | ||
| Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials | Q39933423 | ||
| The effects of alteplase 3 to 6 hours after stroke in the EPITHET-DEFUSE combined dataset: post hoc case-control study. | Q42681461 | ||
| Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). | Q42687753 | ||
| Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke | Q43606519 | ||
| Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke | Q44026712 | ||
| Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. | Q44617267 | ||
| The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions | Q44927361 | ||
| Enhancement of enzymatic fibrinolysis with 2-MHz ultrasound and microbubbles | Q44952822 | ||
| Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab | Q47351597 | ||
| The molecular evolution of genes and proteins: a tale of two serines | Q47377727 | ||
| Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes | Q48481153 | ||
| Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator | Q48481255 | ||
| Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group | Q48913792 | ||
| Thrombolytic therapy with streptokinase in acute ischemic stroke | Q48962264 | ||
| Intravenous alteplase for stroke in those older than 80 years old. | Q51749203 | ||
| Prediction of thrombus resolution after intravenous thrombolysis assessed by CT-based thrombus imaging. | Q53176039 | ||
| Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction | Q56944163 | ||
| Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial | Q56944998 | ||
| Sonothrombolysis With Transcranial Color-Coded Sonography and Recombinant Tissue-Type Plasminogen Activator in Acute Middle Cerebral Artery Main Stem Occlusion | Q57619867 | ||
| The Desmoteplase in Acute Ischemic Stroke Trial (DIAS) | Q61649875 | ||
| Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator | Q68079917 | ||
| Structural Features Mediating Fibrin Selectivity of Vampire Bat Plasminogen Activators | Q71823699 | ||
| Reversal of focal "misery-perfusion syndrome" by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. A case study with 15O positron emission tomography | Q72099180 | ||
| Factor XI deficiency and hemostasis | Q72188624 | ||
| Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association | Q72285059 | ||
| Inhibitor of Platelet Aggregation Present in Saliva of the Vampire Bat Desmodus rotundus | Q72355850 | ||
| Cavitational mechanisms in ultrasound-accelerated thrombolysis at 1 MHz | Q73128929 | ||
| EXPERIMENTAL PLATELET AND COAGULATION THROMBI. A HISTOLOGICAL STUDY OF ARTERIAL AND VENOUS THROMBI OF VARYING AGE IN UNTREATED AND HEPARINIZED RABBITS | Q77093514 | ||
| Perfusion computer tomography: imaging and clinical validation in acute ischaemic stroke | Q82463667 | ||
| Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset | Q83018902 | ||
| Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels | Q84531861 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | thrombolysis | Q1931577 |
| P304 | page(s) | 90-98 | |
| P577 | publication date | 2013-05-31 | |
| P1433 | published in | Journal of stroke | Q26842501 |
| P1476 | title | Review of stroke thrombolytics | |
| P478 | volume | 15 |
| Q30993163 | Acute ischemic stroke imaging: a practical approach for diagnosis and triage |
| Q90055871 | Biomimetic nanoparticle technology for cardiovascular disease detection and treatment |
| Q26781934 | Choosing a Hyperacute Stroke Imaging Protocol for Proper Patient Selection and Time Efficient Endovascular Treatment: Lessons from Recent Trials |
| Q34259078 | Comparative efficacy of different acute reperfusion therapies for acute ischemic stroke: a comprehensive benefit-risk analysis of clinical trials. |
| Q27009122 | Cytoprotective-selective activated protein C therapy for ischaemic stroke |
| Q40053619 | Elongated plant virus-based nanoparticles for enhanced delivery of thrombolytic therapies |
| Q28088710 | Endovascular therapy for ischemic stroke |
| Q37382901 | Facilitating Stroke Management using Modern Information Technology |
| Q50203011 | Histologic features of acute thrombi retrieved from stroke patients during mechanical reperfusion therapy |
| Q27692041 | Intravenous versus intra-arterial thrombolysis in ischemic stroke: a systematic review and meta-analysis |
| Q30367197 | Nanomedicine as a strategy to fight thrombotic diseases. |
| Q33709375 | Neurotherapeutic activity of the recombinant heat shock protein Hsp70 in a model of focal cerebral ischemia in rats |
| Q37382879 | Perfusion patterns of ischemic stroke on computed tomography perfusion |
| Q33626119 | Providing full recovery with single-dose intravenous reteplase in a patient presented to emergency department with acute ischemic stroke |
| Q37382893 | Repeated thrombolytic therapy in patients with recurrent acute ischemic stroke. |
| Q26825758 | Reperfusion therapies of acute ischemic stroke: potentials and failures |
| Q46909712 | Role of NADPH oxidase in total salvianolic acid injection attenuating ischemia-reperfusion impaired cerebral microcirculation and neurons: implication of AMPK/Akt/PKC. |
| Q37639858 | The prognostic values of leukocyte Rho kinase activity in acute ischemic stroke |
| Q47931181 | Tissue plasminogen activator-based nanothrombolysis for ischemic stroke |
| Q38227799 | Tissue regeneration in stroke: cellular and trophic mechanisms |
| Q90538834 | Update in the Early Management and Reperfusion Strategies of Patients with Acute Ischemic Stroke |
| Q48213211 | Value of utilizing both ASPECTS and CT angiography collateral score for outcome prediction in acute ischemic stroke. |
Search more.